Drug intelligence / Profile preview

HXP089

Development stage: Unknown
Lead developer: Haixi New Pharma
Modality: Small Molecules

Overview

HXP089 is a small molecule therapeutic being developed by Fujian Haixi New Drug Creation for the treatment of pancreatic cancer. Classified as a Category 1 chemical drug in China, it is currently undergoing Phase 1 clinical trials. While the specific biological target and mechanism of action have not been publicly disclosed by the developer, the drug is part of a specialized oncology pipeline aimed at addressing high-unmet-need solid tumors.

Beyond the preview

Go deeper on HXP089.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HXP089.

Explore the full profile